← All indications
Diabetic Retinopathy
Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
Drugs by status
Approved for this indication (4)
Phase 4 trials (28)
- mannitol
- simvastatin
- cholestyramine
- empagliflozin
- vitis vinifera
- folic acid
- latanoprost
- hydroquinone
- cyanocobalamin
- conbercept
- pegaptanib
- iodine
- irbesartan
- tesamorelin
- celecoxib
- bevacizumab
- fenofibrate
- glatiramer acetate
- hypochlorous acid
- pyridoxine
- dobesilic acid
- prednisolone
- sodium chloride
- omega-3 fatty acids
- keluo xin
- faricimab
- b55r2
- b55r1
Phase 3 trials (32)
- melatonin
- brimonidine
- axitinib
- vitamin e
- astaxanthin
- prednisone
- amlodipine
- insulin human
- nepafenac
- somatostatin
- ruboxistaurin mesylate
- ocriplasmin
- vitamin c
- octreotide
- acetylsalicylic acid
- sorbinil
- spironolactone
- hyaluronidase (ovine)
- zeaxanthin
- danshen
- infliximab
- triamcinolone
- hydrochlorothiazide
- dapagliflozin
- pemafibrate
- zinc oxide
- brolucizumab-dbll
- brilliant blue g
- lutein
- copper sulfate
- +2 more
Phase 2 trials (56)
- acetazolamide
- rucaparib
- Anecortave
- urea
- bi 1467335
- alpha-lipoic acid
- copper
- darapladib
- doxycycline
- emixustat
- ginkgo
- levosulpiride
- ketorolac
- platelet-rich plasma
- oc-10x
- pf-04523655
- lactose
- polivynilic alcohol
- potassium chloride
- qideng mingmu
- hyaluronic acid
- sirolimus
- squalamine
- akb-9778
- tang ning tongluo
- sulodexide
- sodium acetate
- thr-317
- xanthophyll
- rgx-314
- +26 more
Phase 1 trials (29)
- pimagedine
- acetylcysteine
- canakinumab
- insulin glargine
- autologous serum
- levodopa
- carbidopa
- mb-102
- ms-553
- pan-90806
- adalimumab
- propranolol
- sitagliptin
- fluorescein
- tangwang
- autologous cd34+ cells
- bilberry
- curcumin
- l-epigallocatechin
- methotrexate
- insulin lispro
- yinhsing
- tg-100801
- citicoline
- allorx stem cells®
- bay3283142
- rrg001
- thn391
- npdr-01
Organizations
Organization Involved with Phase 4 Indications (58)
- Regeneron
- Theratechnologies
- Pfizer
- Sanofi
- Novartis
- Allergan
- Bayer
- Hanlim Pharm. Co., Ltd.
- Aarhus University
- Cairo University
- California Retina Consultants
- University of London
- Gottfried Wilhelm Leibniz Universität Hannover
- Hanyang University
- King Khaled Eye Specialist Hospital
- Nanjing Medical University
- National University of Malaysia
- Nihon University
- University of Dundee
- University of Edinburgh
- University of Glasgow
- University of Padova
- University of Rochester
- University of Sydney
- University of Aberdeen
- Asociación para Evitar la Ceguera en México
- University of Catania
- University of Chile
- University of Cologne
- Clinica Alemana de Santiago
- +28 more
Organization Involved with Phase 3 Indications (64)
- Abbott
- Takeda
- ISTA Pharmaceuticals
- Roche
- Bausch & Lomb
- Kowa
- AstraZeneca
- Alcon
- BCN Peptides
- Chromaderm, Inc.
- Hannover Clinical Trial Center GmbH
- Tasly Pharmaceuticals, Inc.
- Vitreoretinal Technologies, Inc.
- National Institutes of Health (NIH)
- National Eye Institute (NEI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Shahid Beheshti University of Medical Sciences
- Huazhong University of Science and Technology
- Greater Houston Retina Research
- Instituto Mexicano del Seguro Social
- Joslin Diabetes Center
- Jaeb Center for Health Research
- Marashi Eye Clinic
- Melbourne Health
- Ophthalmic Consultants of Long Island
- Rush Eye Associates
- Universidad Autonoma de Madrid
- University of Groningen
- University of Guadalajara
- University of Melbourne
- +34 more
Organization Involved with Phase 2 Indications (60)
- Acucela Inc.
- Adverum Biotechnologies, Inc.
- Allegro Ophthalmics, LLC
- Aerpio Therapeutics
- Chengdu Kanghong Biotech Co.,Ltd.
- GlaxoSmithKline
- OcuCure Therapeutics, Inc.
- Regenxbio Inc.
- Semler Research Center Pvt. Ltd.
- Boehringer Ingelheim
- Quark Pharmaceuticals
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Universidad Nacional Autonoma de Mexico
- Jumper, J. Michael, M.D.
- Ajou University
- Elman Retina Group
- Duke University
- Ferris State University
- Hospital Juarez de Mexico
- Manhattan Eye, Ear & Throat Hospital
- Ophthalmic Consultants of Boston
- Ophthalmological Association Edelweiss
- Paracelsus Medical University
- Retina Macula Institute
- Retina Vitreous Associates of Florida
- Schepens Eye Research Institute
- Rocky Mountain Retina Consultants
- Semmelweis University
- St. Erik Eye Hospital
- Universidad Autonoma de Queretaro
- +30 more
Organization Involved with Phase 1 Indications (30)
- Santen Inc.
- MediBeacon
- PanOptica, Inc.
- TargeGen
- Retina Research Foundation
- Emory University
- Retina Institute of Hawaii
- Retinal Consultants of Arizona
- Rutgers University
- The New York Eye & Ear Infirmary
- Texas Retina Associates
- Triemli Hospital
- University of Heidelberg
- University of California, Davis
- Vanderbilt University
- Icahn School of Medicine at Mount Sinai
- University of Minnesota
- University of Mannheim
- Iran University of Medical Sciences
- American University of Beirut
- Tianjin Medical University
- Isfahan University
- Bangladesh Eye Hospital
- Sun Yat-Sen University
- NJMS / UMDNJ
- MacuSight, Inc.
- University of Wisconsin
- Fountain Medical Development Co., Ltd.
- IQVIA
- MingSight-Relin Pharmaceuticals Co., Ltd.
Organization Involved with Other Experimental Indications (17)
- PolyPhotonix Medical
- Fondazione G.B. Bietti, IRCCS
- Narayana Nethralaya
- Centre Hospitalier Intercommunal Creteil
- Eye Clinic Medic Zuljan Jukic
- McMaster University
- Panhandle Eye Group, LLP
- Seoul National University
- University of Southern California
- University of Zagreb
- Yonsei University
- Tel Aviv University
- University of British Columbia
- University of Split
- University of Western Ontario
- Shanghai Municipal Science and Technology Commission
- Velux Fonden